Chen, Cathy
Saxena, Manish http://orcid.org/0000-0001-9964-2692
von Heymann, Christian
Vanassche, Thomas
Jin, James
Lersch, Robert
Köhler, Sabine
Santamaria, Amparo http://orcid.org/0000-0001-7727-880X
Unverdorben, Martin
Colonna, Paolo
Funding for this research was provided by:
Daiichi Sankyo Company
Article History
Received: 17 April 2023
Revised: 21 July 2023
Accepted: 24 July 2023
First Online: 14 August 2023
Competing interests
: CC, JJ, RL, and MU are employees of Daiichi Sankyo. MS reports institutional grants from Recor Medical, Inc., Ablative Solutions, Inc., Applied Therapeutics, and MSD; and consultancy and personal fees from Recor Medical, Inc., Vifor Pharma, Esperion, Inc., Boehringer Ingelheim, Novartis, Daiichi Sankyo Europe, and Daiichi Sankyo UK. CvH reports grants and personal fees from Daiichi Sankyo Europe and Daiichi Sankyo Germany; personal fees from Artcline GmbH, CSL Behring, HICC GbR, Novo Nordisk Pharma, Mitsubishi Pharma, Sobi Pharma, and Shionogi Pharma. TV reports grants and personal fees from Daiichi Sankyo Europe, and personal fees from Daiichi Sankyo Belgium, Bayer, LEO Pharma, and Boehringer Ingelheim. SK reports consulting fees from Daiichi Sankyo. AS reports nothing to disclose. PC reports grants and personal fees from Daiichi Sankyo Europe; personal fees from Daiichi Sankyo Italy, Boehringer Ingelheim, Bayer AG, Pfizer, and Bristol Myers Squibb; and nonfinancial support from the European Society of Cardiology and the Italian Cardiology Association.
: This study was conducted with the approval of institutionalised review boards, and written consent was obtained from all patients.